• 1989-1991 Prediploma Fellow, Institute for Biotechnology, University of Würzburg, Germany 1992-1997 Predoctoral Fellow, Institute for Immunobiology, University of Würzburg, Germany 1998-2001 Postdoctoral Fellow, University of Alabama at Birmingham 2001-2003 Research Instructor, University of Alabama at Birmingham 2003-2005 Research Assistant Professor, University of Alabama at Birmingham 2005- 2008 Assistant Professor, University of Alabama at Birmingham 2005-present Associate Scientist, UAB CFAR 2007-present Director UAB CFAR Flow Cytometry Core Facility 2008-present Associate Professor, University of Alabama at Birmingham
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Bach2 Negatively Regulates T Follicular Helper Cell Differentiation and Is Critical for CD4+ T Cell Memory.Journal of Immunology2019
    2019 High-throughput screening and Bayesian machine learning for copper-dependent inhibitors of: Staphylococcus aureusMetallomics.  11:696-706. 2019
    2018 The phosphatase PPM1A controls monocyte-to-macrophage differentiationScientific Reports.  8. 2018
    2018 Antiretroviral therapy potentiates high-fat diet induced obesity and glucose intoleranceMolecular Metabolism.  12:48-61. 2018
    2018 Regulatory CD4 T cells inhibit HIV-1 expression of other CD4 T cell subsets via interactions with cell surface regulatory proteinsVirology.  516:21-29. 2018
    2017 CD151 expression is associated with a hyperproliferative T cell phenotypeJournal of Immunology.  199:3336-3347. 2017
    2017 A high-throughput compatible assay to evaluate drug efficacy against macrophage passaged Mycobacterium tuberculosisJournal of Visualized Experiments.  2017. 2017
    2017 Mycobacterium tuberculosis exploits the PPM1A signaling pathway to block host macrophage apoptosisScientific Reports.  7. 2017
    2016 8-Hydroxyquinolines are boosting agents of copper-related toxicity in Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy.  60:5765-5776. 2016
    2016 A Macrophage Infection Model to Predict Drug Efficacy Against Mycobacterium TuberculosisASSAY and Drug Development Technologies.  14:345-354. 2016
    2016 Combinatorial phenotypic screen uncovers unrecognized family of extended thiourea inhibitors with copper-dependent anti-staphylococcal activityMetallomics.  8:412-421. 2016
    2016 Protein phosphatase, Mg2+/Mn2+-dependent 1A controls the innate antiviral and antibacterial response of macrophages during HIV-1 and Mycobacterium tuberculosis infectionOncotarget.  7:15394-15409. 2016
    2016 Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemiaJournal of Controlled Release.  224:8-21. 2016
    2015 RNAP II processivity is a limiting step for HIV-1 transcription independent of orientation to and activity of endogenous neighboring promotersVirology.  486:7-14. 2015
    2015 Disulfiram and copper ions kill Mycobacterium tuberculosis in a synergistic mannerAntimicrobial Agents and Chemotherapy.  59:4835-4844. 2015
    2015 Stable phenotypic changes of the host T cells are essential to the long-term stability of latent HIV-1 infectionJournal of Virology.  89:6656-6672. 2015
    2015 The host cell side of latent HIV-1 infectionOncotarget.  6:19920-19921. 2015
    2014 Copper complexation screen reveals compounds with potent antibiotic properties against methicillin-resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy.  58:3727-3736. 2014
    2014 Kinase control of latent HIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivationJournal of Virology.  88:364-376. 2014
    2013 An AP-1 binding site in the enhancer/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infectionJournal of Virology.  87:2264-2277. 2013
    2013 Copper-boosting compounds: A novel concept for antimycobacterial drug discoveryAntimicrobial Agents and Chemotherapy.  57:1089-1091. 2013
    2012 Host factor transcriptional regulation contributes to preferential expression of HIV type 1 in IL-4-producing CD4 T cellsJournal of Immunology.  189:2746-2757. 2012
    2012 Selected drugs with reported secondary cell-differentiating capacity prime latent HIV-1 infection for reactivationJournal of Virology.  86:9055-9069. 2012
    2012 Effective Non-Viral Delivery of siRNA to Acute Myeloid Leukemia Cells with Lipid-Substituted PolyethyleniminesPLoS ONE.  7. 2012
    2012 Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-κB activityJournal of Virology.  86:4548-4558. 2012
    2012 Validating a firefly luciferase-based high-throughput screening assay for antimalarial drug discoveryASSAY and Drug Development Technologies.  10:61-68. 2012
    2011 Facts and fiction: Cellular models for high throughput screening for HIV-1 reactivating drugsCurrent HIV Research.  9:568-578. 2011
    2011 Targeted disruption of the CCR5 gene in human hematopoietic stem cells stimulated by peptide nucleic acidsCell Chemistry Biology.  18:1189-1198. 2011
    2011 Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitorsVirology.  415:56-68. 2011
    2011 A screen to identify small molecule inhibitors of protein-protein interactions in mycobacteriaASSAY and Drug Development Technologies.  9:299-310. 2011
    2010 Hit-and-run stimulation: A novel concept to reactivate latent HIV-1 infection without cytokine gene inductionJournal of Virology.  84:8712-8720. 2010
    2010 Suppressor of cytokine signaling 3 inhibits antiviral IFN-β signaling to enhance HIV-1 replication in macrophagesJournal of Immunology.  185:2393-2404. 2010
    2010 Adjusting transgene expression levels in lymphocytes with a set of inducible promotersJournal of Gene Medicine.  12:501-515. 2010
    2009 Effective activation alleviates the replication block of CCR5-tropic HIV-1 in chimpanzee CD4+ lymphocytesVirology.  394:109-118. 2009
    2009 Determinants of the Establishment of Human Immunodeficiency Virus Type 1 LatencyJournal of Virology.  83:3078-3093. 2009
    2009 Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasmaJournal of Virology.  83:1240-1259. 2009
    2008 The quality of chimpanzee T-cell activation and simian immunodeficiency virus/human immunodeficiency virus susceptibility achieved via antibody-mediated T-cell receptor/CD3 stimulation is a function of the anti-CD3 antibody isotypeJournal of Virology.  82:10271-10278. 2008
    2007 Optimization of HIV-1 infectivity assaysBioTechniques.  43:589-594. 2007
    2007 High throughput drug screening for human immunodeficiency virus type 1 reactivating compoundsASSAY and Drug Development Technologies.  5:181-189. 2007
    2006 A high-throughput drug screening system for HIV-1 transcription inhibitorsJournal of Biomolecular Screening.  11:807-815. 2006
    2006 Nef-Mediated Suppression of T Cell Activation Was Lost in a Lentiviral Lineage that Gave Rise to HIV-1Cell.  125:1055-1067. 2006
    2006 T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replicationBioTechniques.  40:91-100. 2006
    2005 Erratum: Dynamics of HIV-1 recombination in its natural target cells (Proceedings of the National Academy of Sciences (March 2004) 101:12 (4204-4209))Proceedings of the National Academy of Sciences.  102:1808. 2005
    2005 Amphotericin-B-mediated reactivation of latent HIV-1 infectionVirology.  331:106-116. 2005
    2005 Tat inhibitors, a new approach: interview with Olaf Kutsch, Ph.D. Interview by John S. James.AIDS treatment news.  4-5. 2005
    2004 Bis-Anthracycline Antibiotics Inhibit Human Immunodeficiency Virus Type 1 TranscriptionAntimicrobial Agents and Chemotherapy.  48:1652-1663. 2004
    2004 Dynamics of HIV-1 recombination in its natural target cellsProceedings of the National Academy of Sciences.  101:4204-4209. 2004
    2003 CD154-CD40-induced reactivation of latent HIV-1 infectionVirology.  314:261-270. 2003
    2003 Potenziale des Skill-ManagementsWirtschaftsinformatik.  45:227-229. 2003
    2002 HIV type 1 abrogates TAP-mediated transport of antigenic peptides presented by MHC class IAIDS Research and Human Retroviruses.  18:1319-1325. 2002
    2002 Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latencyJournal of Virology.  76:8776-8786. 2002
    2002 Tumor necrosis factor-related apoptosis-inducing ligand induces caspase-dependent interleukin-8 expression and apoptosis in human astroglioma cellsMolecular and Cellular Biology.  22:724-736. 2002
    2001 CXC chemokine receptor 4 expression and function in human astroglioma cellsJournal of Immunology.  166:2695-2704. 2001
    2000 Induction of the chemokines interleukin-8 and IP-10 by human immunodeficiency virus type 1 Tat in astrocytesJournal of Virology.  74:9214-9221. 2000
    1997 Rapid and selective depletion of CD4 + T lymphocytes and preferential loss of memory cells on interaction of mononuclear cells with HIV-1 glycoprotein-expressing cellsJournal of Acquired Immune Deficiency Syndromes and Human Retrovirology.  16:74-82. 1997

    Research Overview

  • HIV-1 research in my laboratory is focused on finding a cure for HIV-1 infection. This goal is pursued at the level of basic research and drug discovery. Basic research efforts focus on advancing our understanding of the molecular mechanisms controlling latent HIV-1 infection. The insights gained from these studies can then be translated into drug discovery efforts, either by developing drug screening assays and performing drug screens, or by trying to reposition existing drugs.

    Keywords: HIV-1 eradication, HIV-1 latency, drug discovery
  • Education And Training

  • Doctor of Philosophy Level Degree in Immunology, 1997
  • Full Name

  • Olaf Kutsch